Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "exclusive"

573 News Found

Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients
News | March 20, 2026

Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients

India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease


Zydus and Torrent Pharma to co-market Semaglutide injection in India
News | March 19, 2026

Zydus and Torrent Pharma to co-market Semaglutide injection in India

Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device


Mankind Pharma acquires Rivotril brand for India
News | March 19, 2026

Mankind Pharma acquires Rivotril brand for India

Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions


Zydus, Lupin join forces to expand access to semaglutide in India
News | March 18, 2026

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus


China’s NMPA approves Zydus-licensed anaemia drug Desidustat
News | March 15, 2026

China’s NMPA approves Zydus-licensed anaemia drug Desidustat

Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients


Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
News | March 14, 2026

Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan

Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema


MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
Biotech | March 14, 2026

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions


Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
News | March 10, 2026

Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development

The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications


Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026
Biotech | March 07, 2026

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations